Scientists found a sneaky way to stop cold viruses from replicating in mammalian cells by disabling a protein not in the virus but in the cells they infect.
Mammalian cells use a label to distinguish self from non-self circular RNA molecules. Foreign molecules can trigger anti-cancer immune responses.
In a recent Stanford podcast, food allergy expert Kari Nadeau explains the latest research on predicting, preventing and treating allergies.
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
Selectively subduing a set of cells that migrate to the brain after a stroke occurs could meaningfully treat the stroke even days later.
In this In the Spotlight, Rebecca Saenz, a recent allergy and immunology fellow, describes her evolution as a physician/scientist and entrepreneur.
A method that broadens the pool of potential donors for stem cell transplants recently saved two young brothers from a severe genetic disease.
Third-year medical student Neil Rens explains why he chooses to advocate for stricter vaccination requirements in California.
Osteoarthritis has traditionally been thought to be an inevitable result of wear and tear. But it's now clear the immune system is playing a leading role.
Stanford researchers have developed a technique to encourage the immune system to target a section of the flu virus that is conserved year to year.
Stanford scientists and collaborators have harnessed CRISPR to replace the mutated gene underpinning the devastating immune disease, SCID-X1.
P. aeruginosa, a type of bacteria, is increasingly drug-resistant, and there's no vaccine against it. But it has a recently discovered Achilles heel.
Scientists have modified immune cells, imbuing them with the ability to not only detect, but reveal, the presence of a tumor.
Cracking the crystal structure of a protein complex centered around a major immune signaling protein, interferon-gamma, may speed its medical use.
A new blood test measures the DNA fragments of lung transplant donors in the blood of recipients, in hopes of preventing organ rejection and saving lives.
Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.